title: Targeted treatments for multiple myeloma: specific role of carfilzomib.
abstract: Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly diagnosed setting, and Phase III studies are entering their final analysis. Data continue to grow to support its use as both single-agent therapy and in combination with immunomodulatory and other novel agents. This review discusses the role of carfilzomib in the treatment of multiple myeloma. Its mechanism of action, pharmacokinetics, and role in clinical management will be reviewed.
authors.affiliation: Department of Internal Medicine, St Mary's Health Center, Washington University in St Louis, St Louis, USA.
authors.forename: Dhivya
authors.initials: D
authors.lastname: Sugumar
authors.affiliation: Department of Medicine, Division of Oncology, Washington University in St Louis, St Louis, USA.
authors.forename: Jesse
authors.initials: J
authors.lastname: Keller
authors.affiliation: Department of Medicine, Division of Oncology, Washington University in St Louis, St Louis, USA.
authors.forename: Ravi
authors.initials: R
authors.lastname: Vij
keywords: novel agents; proteasome inhibitor; relapsed and refractory; targeted therapy